<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052923</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258802</org_study_id>
    <secondary_id>ECOG-E2499</secondary_id>
    <secondary_id>CALGB-50205</secondary_id>
    <secondary_id>CALGB-E2499</secondary_id>
    <nct_id>NCT00052923</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma</brief_title>
  <official_title>Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Combining chemotherapy with stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
      Monoclonal antibodies, such as rituximab, can locate tumor cells and either kill them or&#xD;
      deliver tumor-killing substances to them without harming normal cells. It is not yet known&#xD;
      whether stem cell transplantation is more effective with or without rituximab in treating&#xD;
      relapsed or progressive B-cell diffuse large cell lymphoma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of stem cell transplantation&#xD;
      with or without rituximab in treating patients who have relapsed or progressive B-cell&#xD;
      diffuse large cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare disease-free survival of patients with relapsed or progressive B-cell diffuse&#xD;
           large cell lymphoma undergoing stem cell transplantation with or without post-transplant&#xD;
           rituximab.&#xD;
&#xD;
        -  Evaluate the effect of rituximab, administered post-transplant, on the procedure-related&#xD;
           mortality of these patients.&#xD;
&#xD;
        -  Determine the potential infectious complications of the addition of this drug to&#xD;
           autologous stem cell transplantation in these patients.&#xD;
&#xD;
        -  Compare overall survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      relapse (relapsed more than 6 months after either initial complete remission [CR] or CR with&#xD;
      positive positron emission tomography or MRI [gallium] vs failed to achieve initial CR or&#xD;
      relapsed within 6 months after either initial CR or CR with positive PET or MRI [gallium])&#xD;
      and prior rituximab (yes vs no).&#xD;
&#xD;
      Stem cell mobilization&#xD;
&#xD;
        -  Patients receive rituximab IV over 4-8 hours on days 1 and 5. Patients also receive&#xD;
           cyclophosphamide IV over 2 hours on day 8 and filgrastim (G-CSF) subcutaneously (SC)&#xD;
           beginning on day 9 and continuing until the last day of apheresis. Stem cells are&#xD;
           collected over 1-3 days.&#xD;
&#xD;
      Preparative regimen&#xD;
&#xD;
        -  Regimen A (patients who have received prior radiotherapy or are ≥ 61 years of age):&#xD;
           Patients receive carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day&#xD;
           -4, and cyclophosphamide IV over 2 hours on day -2.&#xD;
&#xD;
        -  Regimen B (all other patients): Patients undergo total body irradiation twice daily on&#xD;
           days -8 to -5. Patients receive etoposide IV over 4 hours on day -4 and cyclophosphamide&#xD;
           IV over 2 hours on day -2.&#xD;
&#xD;
      Stem cells are reinfused on day 0. Patients are then randomized to one of two post-transplant&#xD;
      treatment arms.&#xD;
&#xD;
      Post-transplant treatment&#xD;
&#xD;
        -  Arm I (rituximab): Patients receive G-CSF SC beginning on day 6 and continuing until&#xD;
           blood counts recover. Patients receive rituximab IV over 4-8 hours every 7 days for 4&#xD;
           doses, starting on day 45 post-transplant. Course of rituximab is repeated beginning on&#xD;
           day 180 post-transplant.&#xD;
&#xD;
        -  Arm II (no rituximab): Patients receive G-CSF as in arm I. Patients are followed for 10&#xD;
           years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 427 patients will be accrued for this study within 3.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure-related mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential infectious complications of the addition of rituximab to autologous stem cell transplantation</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">427</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of diffuse large cell lymphoma and meeting the following criteria:&#xD;
&#xD;
               -  B-cell type with expression of CD20 either at diagnosis or at relapse&#xD;
&#xD;
               -  Relapse after having achieved an initial complete remission (CR) or failure to&#xD;
                  achieve initial CR (residual radiographic abnormalities after primary therapy&#xD;
                  allowed if these abnormalities are also positive by positron emission tomography&#xD;
                  or MRI [gallium])&#xD;
&#xD;
               -  No newly diagnosed disease&#xD;
&#xD;
          -  No progressive or stable disease to most recent salvage therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 60% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 2 years except basal cell skin cancer or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  No active infection requiring oral or IV antibiotics&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior immunotherapy regimens&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
               -  Addition of radiation or a monoclonal antibody to chemotherapy is considered one&#xD;
                  treatment regimen if the addition was part of the initial treatment plan&#xD;
&#xD;
               -  Addition of these therapies due to lack of response or poor response would be&#xD;
                  considered an additional treatment regimen whether given in front-line or salvage&#xD;
                  setting&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior radiotherapy regimens&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian W. Flinn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles A. Linker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <removed_countries>
    <country>Israel</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

